In the news

Applied Clinical Trials
28 August 2012

ARTICLE: The advantages of using ePROs in diabetes clinical trials and studies

This September will see the publication in Applied Clinical Trials the peer-reviewed paper by Keith Meadows and Chris Hall – ‘ePRO on diabetes Studies’ which describes some of the key advantages in the use of ePROs in diabetes clinical trials and studies. 

Diabetes has rapidly become a global epidemic affecting more than 238 million people. That number is expected to increase to 438 million people by the year 2030. The economic burden of the disease totaled $376 billion in 2010. As such, biopharmaceutical companies and researchers around the world are working to identify new, effective and safe treatments to help this growing patient population. 

Diabetes clinical research often includes patient reported outcomes (PROs) to measure symptoms and safety over the course of the trial, quality of life, and the economic burden of the disease. Data are collected directly from patients on diaries and/or questionnaires, which are either printed on paper or available on electronic devices. The use of electronic patient reported outcome (ePRO) data in clinical research is increasing as regulatory authorities acknowledge the credibility of such data, particularly in comparison to paper and pencil self-reports completed in unsupervised settings.

For all press and media enquiries please contact